• 1. An approach to 7-aza-1-phosphanorbornane complexes: strain promoted rearrangement of 1-iminylphosphirane complexes and cycloaddition with olefins?
  Yang Xu,Min Wang,Donghui Wei,Rongqiang Tian,Zheng Duan,Fran?ois Mathey Dalton Trans., 2019,48, 5523-5526
• 2. An asymmetric supercapacitor based on controllable WO3 nanorod bundle and alfalfa-derived porous carbon?
  Kanjun Sun,Fengting Hua,Shuzhen Cui,Yanrong Zhu,Hui Peng,Guofu Ma RSC Adv., 2021,11, 37631-37642
• 3. An artificial photosynthesis system comprising a covalent triazine framework as an electron relay facilitator for photochemical carbon dioxide reduction?
  Siquan Zhang,Shengyao Wang,Liping Guo,Hao Chen,Bien Tan,Shangbin Jin J. Mater. Chem. C, 2020,8, 192-200
• 4. An artificial enzyme cascade amplification strategy for highly sensitive and specific detection of breast cancer-derived exosomes?
  Huiying Xu,Lu Zheng,Yu Zhou,Bang-Ce Ye Analyst, 2021,146, 5542-5549
• 5. An apparatus for testing water by measurement of its electrical conductivity
  Analyst, 1912,37, 538-543

Chemical Profile of 4-Bromo-5-methylpyrazolo[1,5-a]pyridine (CAS No. 1345121-29-0)

4-Bromo-5-methylpyrazolo[1,5-a]pyridine (CAS No. 1345121-29-0) is a heterocyclic compound that has garnered significant attention in the field of pharmaceutical and medicinal chemistry due to its versatile structural framework and potential biological activities. This compound belongs to the pyrazolo[1,5-a]pyridine class, which is known for its broad spectrum of pharmacological properties, including antimicrobial, anti-inflammatory, and anticancer effects. The presence of both bromine and methyl substituents in its structure enhances its reactivity and makes it a valuable scaffold for further chemical modifications and drug discovery initiatives.

The structural motif of 4-Bromo-5-methylpyrazolo[1,5-a]pyridine consists of a fused bicyclic system comprising a pyrazole ring and a pyridine ring. This unique arrangement contributes to its distinct electronic and steric properties, which are crucial for interactions with biological targets. The bromine atom at the 4-position serves as a reactive handle for various chemical transformations, such as Suzuki-Miyaura cross-coupling reactions, allowing for the introduction of diverse functional groups. Meanwhile, the methyl group at the 5-position influences the compound's electronic distribution and can modulate its binding affinity to biological receptors.

In recent years, there has been growing interest in heterocyclic compounds like 4-Bromo-5-methylpyrazolo[1,5-a]pyridine due to their prevalence in natural products and synthetic drugs. The pyrazolo[1,5-a]pyridine scaffold has been extensively studied for its ability to inhibit various enzymes and receptors involved in disease pathways. For instance, derivatives of this class have shown promise in targeting kinases, which are key players in cancer signaling pathways. The brominated derivatives, in particular, have been explored for their enhanced binding affinity and metabolic stability.

One of the most compelling aspects of 4-Bromo-5-methylpyrazolo[1,5-a]pyridine is its potential as a pharmaceutical intermediate. Researchers have leveraged its structural features to develop novel inhibitors with therapeutic applications. A notable example comes from studies on Janus kinases (JAKs), which are implicated in inflammatory diseases such as rheumatoid arthritis. By modifying the bromine substituent or introducing additional functional groups, scientists have generated analogs that exhibit potent JAK inhibition with improved selectivity over other kinases. These findings highlight the compound's significance in the development of targeted therapies.

The synthetic accessibility of 4-Bromo-5-methylpyrazolo[1,5-a]pyridine also contributes to its appeal in drug discovery programs. The compound can be synthesized through multi-step organic reactions starting from commercially available precursors. Recent advances in catalytic methods have further streamlined its preparation, enabling high yields and purity levels suitable for preclinical studies. This ease of synthesis makes it an attractive candidate for high-throughput screening campaigns aimed at identifying new drug candidates.

Moreover, the biological activity of 4-Bromo-5-methylpyrazolo[1,5-a]pyridine has been explored in various disease models. Preclinical studies have demonstrated its potential in modulating pathways relevant to neurodegenerative disorders. For example, researchers have observed that certain derivatives of this compound can inhibit the aggregation of amyloid-beta peptides, a hallmark protein in Alzheimer's disease. Such findings underscore the compound's therapeutic potential and justify further investigation into its mechanism of action.

The pharmacokinetic properties of 4-Bromo-5-methylpyrazolo[1,5-a]pyridine are also worth mentioning. Due to its heterocyclic nature and functional groups, it exhibits favorable solubility and bioavailability profiles when appropriately formulated. This characteristic is essential for developing orally administered drugs that can reach target tissues effectively. Computational modeling studies have been employed to predict how structural modifications might influence these pharmacokinetic parameters, providing insights into optimizing drug design.

In conclusion,4-Bromo-5-methylpyrazolo[1,5-a]pyridine (CAS No. 1345121-29-0) represents a promising chemical entity with significant potential in pharmaceutical research. Its unique structural features, coupled with its synthetic tractability and biological activity, make it a valuable tool for developing new therapeutic agents. As research continues to uncover new applications for this compound, it is likely to play an increasingly important role in addressing unmet medical needs across multiple therapeutic areas.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)